Finance

Lists
Why is AIM down 3.36%?
Dive Deeper
AIM:NYSEAMERICAN
AIM ImmunoTech Inc
$0.14
-3.36%
(-0.0050) 1D
$0.14
+0.28% (+0.00040)
Pre-market
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AIM...
Open
$0.15
High
$0.15
Low
$0.14
Mkt. cap
5.68M
Avg. vol.
586.32K
Volume
27.06K
52-wk high
$1.88
52-wk low
$0.12
EPS
-$3.93
Beta
1.32
Shares outstanding
39.92M
No. of employees
20
Open
$0.15
High
$0.15
Low
$0.14
Mkt. cap
5.68M
Avg. vol.
586.32K
Volume
27.06K
52-wk high
$1.88
52-wk low
$0.12
EPS
-$3.93
Beta
1.32
Shares outstanding
39.92M
No. of employees
20
News stories
From web sources and news partners
Profile
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. The company has created an immunomodulatory double stranded RNA drug called Ampligen. It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
About AIM ImmunoTech Inc
CEO-
Employees20
Founded1966
HeadquartersPhiladelphia, Pennsylvania, United States
SectorHealth Care
IndustryBiotechnology
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
21.00K
22.00K
26.00K
22.00K
Cost of goods sold
40.00K
4.00K
5.00K
7.00K
Cost of revenue
40.00K
4.00K
5.00K
7.00K
Research and development expenses
999.00K
381.00K
589.00K
846.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.93M
1.86M
2.94M
2.13M
Operating expense
2.93M
2.24M
3.53M
2.97M
Total operating expenses
2.97M
2.25M
3.54M
2.98M
Operating income
-2.95M
-2.23M
-3.51M
-2.96M
Other non operating income
-942.00K
-500.00K
-
74.00K
EBT including unusual items
-4.18M
-3.02M
-3.79M
-3.14M
EBT excluding unusual items
-4.18M
-3.02M
-3.79M
-3.14M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4.18M
-3.02M
-3.79M
-3.14M
Net profit margin
-19,880.95%
-13,740.91%
-14,569.23%
-14,286.36%
Earnings per share
-0.44
-0.69
-0.43
-0.21
Interest and investment income
110.00K
8.00K
21.00K
-
Interest expense
-391.00K
-304.00K
-295.00K
-259.00K
Net interest expenses
-281.00K
-296.00K
-274.00K
-259.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.91M
-2.18M
-2.98M
-2.68M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps